Industry Recognized Expert in Psychedelics and Related Safety Guidelines
NEW YORK, Nov. 09, 2020 — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced it has formed a Scientific Advisory Board for evaluating opportunities to advance strategies related to the use of psychedelic and psilocybin drug therapies. The company appointed addiction medicine and drug dependence researcher Dr. Matthew W. Johnson, Ph.D. as a member of the advisory board.
“Psilocybin research is one of the most intriguing and fastest growing areas of biotechnology, as it is believed that psychedelics hold the potential to address some of the largest and most challenging diseases such as depression, CNS related disorders, anxiety, PTSD, and Parkinson’s,” said Eric Weisblum, CEO of Silo Pharma. “The establishment of our Scientific Advisory Board reflects our commitment to pursuing multiple, strategic opportunities for privately-funded research. An advisory board of expert researchers will be instrumental in guiding us through the process of selecting and funding the best opportunities for the advancement of our mission and to maximize returns.”
Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction and risk behavior. Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.
“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit of market opportunities for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”
Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics. Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.
Dr. Johnson earned his Ph.D. in experimental psychology at the University of Vermont in 2004 and his Bachelor of Science at Eastern Oregon University in 1998.
Safe Harbor and Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Email: brett[email protected]